Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET Mutation Associated with Responsiveness to Crizotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2015

Waqar Saiama N, Morgensztern Daniel, Sehn Jennifer

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents
Share to Crizotinib
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Share to Retreatment

Source

Open in PubMed Open full text

Identifiers

PMID: 25898962
DOI: 10.1097/JTO.0000000000000478
PMCID: PMC4408879

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET Mutation Associated with Responsiveness to Crizotinib.PMID 25898962Read ↗

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.Semantic proximity Read ↗

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.Semantic proximity Read ↗

MET-Mutated NSCLC with Major Response to Crizotinib.Semantic proximity Read ↗

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.Semantic proximity Read ↗

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersSemantic proximity Read ↗

A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.Semantic proximity Read ↗

[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].Semantic proximity Read ↗

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.Semantic proximity Read ↗

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Semantic proximity Read ↗

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.Semantic proximity Read ↗

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.